Targeted estrogen/progestogen replacement therapy for osteoporosis: calculation of health care cost savings

Abstract

Osteoporosis is a crippling affliction in which bone mass decreases, making it more susceptible to fracture. In postmenopausal women it presents most often as a hip, spinal, or forearm fracture. Adult women face a 15% lifetime risk of a hip fracture, and the annual costs of hip fractures alone are estimated at $7.3 billion in the United States. Since the 1970s, estrogen/progestogen therapy has been recognized as an effective intervention that reduces the risk of fractures. Recently, the development of methods for accurately determining bone mass and thus helping to predict bone fracture risk has made this intervention attractive for use in a targeted population. This report analyzes the health care costs and calculates the cost savings of coupling bone mineral density screening at the time of menopause with long-term estrogen/progestogen therapy for those most at risk for developing fractures. The model assumes that a cohort of 100,000 American white women, aged 50, are screened for bone mineral density and that 90% of the high-risk group (density less than 0.85 g/cm3) and 70% of the mid-risk group (density between 0.85 and 1.00 g/cm3) elect to take hormone replacement therapy for 15 years. Based on calculations of the costs of screening and hormone replacement therapy, and the savings in cost of treatment and lost productivity from reduced fractures, it is estimated that the present value of savings in cost of illness for this cohort over a 40-year period is $5.1 million.(ABSTRACT TRUNCATED AT 250 WORDS)

Cost-effectiveness research in osteoporosis

“…Two of these studies concluded that screening followed by therapy with HRT for 15 years was cost-effective Clark and Schuttinga, 1992]. However, neither of these studies incorporated risk estimates for any of the nonskeletal effects of HRT including breast cancer, endometrial cancer, and heart disease.…”

“…Bone density screening followed by HRT was assessed in three studies OTA, 1995;Clark and Schuttinga, 1992]. Two of these studies concluded that screening followed by therapy with HRT for 15 years was cost-effective Clark and Schuttinga, 1992].…”

A review of economic evaluation in osteoporosis

“…Bone density screening followed by HRT was assessed in 3 studies (8,10,43). Two of these studies concluded that screening followed by therapy with HRT for 15 years was cost-effective (8,43).…”

“…Two of these studies concluded that screening followed by therapy with HRT for 15 years was cost-effective (8,43). However, neither of these studies incorporated risk estimates for any of the nonskeletal effects of HRT, including breast cancer, endometrial cancer, and heart disease.…”

Secretion Effect of Estrogen of Different Growth Stages of Silkworm (Bombyx mori L.)

“…These symptoms caused by deficit of estrogen are called Pre-AND Post-menopausal syndrome and PMS (Clarke et al, 1992;Cumming et al, 1990). Conjugated equine estrogen, CEE, or chemosynthesis medical supply has been used recently to reduce or cure these symptoms.…”